Baxter Healthcare Corporation received FDA approval for Intravenous Ephedrine Sulfate (ANDA216740) on July 8, 2026, entering a market poised for potential price volatility as the patent cliff for generic IV neuromuscular blockers concludes later that year. The approval allows for the launch of a critical alternative where generics are scarce, potentially capturing share during the anticipated shortage of branded injectable epinephrine.